Dedicated to Conquering Heart Failure
A clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease
COVID-19 and CVD
Cardiol has been approved by the FDA for a Phase II/III clinical trial to test the efficacy of CardiolRx™ in improving outcomes for COVID-19 patients with cardiovascular disease (CVD).
Learn More
Acute Myocarditis
Cardiol is planning a Phase II international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.
Learn More
Heart Failure
Committed to conquering a serious condition that affects more than 26 million people globally.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™
April 12, 2021
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™
TSX:CRDL OTCQX:CRTPF FSE:CT9
